Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring
Top Cited Papers
Open Access
- 27 February 2021
- Vol. 12 (3), 349
- https://doi.org/10.3390/genes12030349
Abstract
The minimally—or non-invasive detection of circulating tumor-derived components in biofluids, such as blood, liquid biopsy is a revolutionary approach with significant potential for the management of cancer. Genomic and transcriptomic alterations can be accurately detected through liquid biopsies, which provide a more comprehensive characterization of the heterogeneous tumor profile than tissue biopsies alone. Liquid biopsies could assist diagnosis, prognosis, and treatment selection, and hold great potential to complement current surveilling strategies to monitor disease evolution and treatment response in real-time. In particular, these are able to detect minimal residual disease, to predict progression, and to identify mechanisms of resistance, allowing to re-orient treatment strategies in a timelier manner. In this review we gathered current knowledge regarding the role and potential of liquid biopsies for the diagnosis and follow-up of cancer patients. The presented findings emphasize the strengths of liquid biopsies, revealing their chance of improving the diagnosis and monitoring of several tumor types in the near future. However, despite growing evidence supporting their value as a management tool in oncology, some limitations still need to be overcome for their implementation in the routine clinical setting.Keywords
This publication has 98 references indexed in Scilit:
- Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in MelanomaCancer Discovery, 2016
- Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancerGastric Cancer, 2016
- Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assayOncotarget, 2016
- Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Oncotarget, 2016
- Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screeningOncotarget, 2015
- Evaluation of a biomarker based blood test for monitoring surgical resection of oral squamous cell carcinomasClinical Oral Investigations, 2015
- HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot studyGastric Cancer, 2014
- Stabilization of cell-free RNA in blood samples using a new collection deviceClinical Biochemistry, 2012
- The origin of extracellular DNA during the clearance of dead and dying cellsAutoimmunity, 2007
- Rapid Clearance of Fetal DNA from Maternal PlasmaAmerican Journal of Human Genetics, 1999